GlassScriptPhysician profile
Thomas J Reid
NPI 1295742153
$5,243.06
in general payments reported to CMS, 2019-2025
49 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $60.03 · 2021: $629 · 2022: $642 · 2023: $1,025 · 2024: $1,020 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.48 |
| Education | $344.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $660.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $471.99 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $468.36 | 2019-2024 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $372.45 | 2019-2025 | Imfinzi, Lynparza |
| Amgen INC. | $363.55 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Novartis Pharmaceuticals Corporation | $263.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $166.07 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Gilead Sciences, INC. | $165.50 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $160.26 | 2019-2025 | |
| Abbvie INC. | $156.58 | 2023-2024 | |
| Kite Pharma, INC. | $151.15 | 2019-2023 | |
| Pharmaessentia USA Corporation | $144.40 | 2025 | Besremi |
| Sumitomo Pharma America, INC. | $133.81 | 2023-2025 | Orgovyx |
| Tempus Ai, INC | $132.27 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $117.33 | 2022-2024 | Fotivda |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $111.48 | 2019-2020 | |
| Celgene Corporation | $106.64 | 2022-2024 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $103.45 | 2021-2024 | Xtandi, Padcev |
| Emd Serono, INC. | $97.78 | 2021-2023 | Bavencio |
| Incyte Corporation | $88.69 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2024 | Fruzaqla |
| Array Biopharma INC | $74.94 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Glaxosmithkline, LLC. | $74.12 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $64.75 | 2019-2025 | Hemlibra, Venclexta, Lunsumio |
| Pharmacyclics LLC, An Abbvie Company | $38.18 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.74 | 2023-2025 | |
| Taiho Oncology, INC. | $34.99 | 2024 | |
| Tesaro, INC. | $28.38 | 2019 | |
| Dova Pharmaceuticals | $27.38 | 2019-2021 | |
| Daiichi Sankyo INC. | $24.87 | 2024 | Enhertu |
| Fennec Pharmaceuticals, INC. | $21.35 | 2023 | Pedmark |
| Biogen, INC. | $21.29 | 2023 | Tysabri |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Exelixis INC. | $20.49 | 2025 | Cabometyx |
| Sobi, INC | $19.77 | 2023 | |
| Beone Medicines USA, INC. | $19.63 | 2025 | Brukinsa |
| Epizyme, INC. | $19.25 | 2021 | |
| Rigel Pharmaceuticals, INC. | $19.01 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.92 | 2024 | Onivyde |
| Novocure INC. | $17.63 | 2019 | |
| Cti Biopharma Corp. | $17.20 | 2023 | Vonjo |
| Myovant Sciences INC. | $17.19 | 2022 | |
| Eusa Pharma (US) LLC | $16.85 | 2019 | |
| Lilly USA, LLC | $16.43 | 2021 | |
| Stemline Therapeutics INC. | $16.20 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $15.38 | 2019 | |
| Springworks Therapeutics, INC. | $14.66 | 2025 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $14.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.